Optimal Duration of Maintenance Checkpoint Inhibitor Therapy in Patients With Advanced NSCLC

JCO Oncol Pract. 2021 Aug;17(8):472-474. doi: 10.1200/OP.21.00059. Epub 2021 May 3.

Authors

Nikhil Shukla¹, Nasser Hanna¹, Greg Durm¹

Affiliation

¹ Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN.

PMID: 33939474
DOI: 10.1200/OP.21.00059

No abstract available

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Humans
Lung Neoplasms* / drug therapy